Fragmento 176-191El fragmento 176-191 es una pequeña sección de la secuencia de la hormona del crecimiento humano (hGH) que tiene modelos para mejorar la quema de grasa y cambiar el metabolismo hacia el modo en que se ha demostrado en el mantenimiento de la masa magra [1]-[3]. La investigación también sugiere que el fragmento 176-191 también carece de muchos de los efectos secundarios causados por la hGH, como disminución de la sensibilidad a la insulina, crecimiento de los huesos largos y anedema. Dicho esto, el fragmento podría contribuir a los mecanismos fisiológicos normales que controlan la secreción de GH y, por lo tanto, podría afectar positivamente los niveles de GH según estudios de investigación recientes.CJC-1295CJC-1295 could counteract the GH effects of fragment 176-191 as it is a synthetic growthhormone releasing hormone and therefore stimulates the release of G[4]. CJC-1295 actsto increase basal and peak levels of GH and has also been shown to increase freeplasma levels of GH. Only free GH is biologically active. CJC-1295 can there forecompensate for a normal physiologic response to fragment 176-191. This would allow forthe benefits of fragment 176-191 to be realized without having any impact on normal GHsecretion.
To further boost GH secretion above basal levels and to particularly affect peak GHsecretion, lpamorelin could be added to the mix, pamorelin is a growth hormone secretagogue receptor agonist that has been shown in animal studies to have potent andspecific effects on GH secretion while having very limited side effects[5]. lpamorelin hasalso been shown to be highly beneficial to bone mineralization and insulin control inanimal models[6], [7]. lpamorelin is a short-acting peptide whereas CJC-1295 is a longer.acting peptide. The former provides rapid onset GH release while the latter acts to raiseGH secretion over longer periods and maintain normal physiologic secretion patterns[8], [9]Acerca del autorLa literatura anterior fue investigada, editada y organizada por el Dr. E. Logan, M.D. El Dr. ELogan tiene un doctorado de la Facultad de Medicina de la Universidad Case Western Reserve y una licenciatura en Ciencias. en biología molecular.Revista CientíficaAutorDr. Dominigue Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Oraanic Chemistryirom the University of Paris Xl, ICSN, Orsay, France with Nobel Laureate Sir Derek H. RBarton as Research Advisor. He completed his Post-Doctoral Research at the Universityof California. Berkeley. He studied the potential of CJC-1295 as a long lasting GRFanalog and also held various leadership positions involving peptide research andtechnologies at lpsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon hasserved as a Director for Enobia (acquired by Alexion) and Neuronax and as a member ofthe Scientific Advisory Board of Syntaxin (acquired by lpsen) and Biosortia. Henow brings 30 years of executive and scientific leadership experience to the EpivaxOncology team.
Dr. Dominique Bridon is being referenced as one of the leading scientists involved in theresearch and development of CJC-1295. In no way is this doctor/scientist endorsing oradvocating the purchase, sale, or use of this product for any reason. There is no affiliationor relationship, implied or otherwise, between PEPTIDE GURUS and this doctor. Theourpose of citing the doctor is to acknowledge, recognize, and credit the exhaustiveresearch and development efforts conducted by the scientists studying this peptide. Dr.Dominique Bridon is listed in [10]under the referenced citations.Recursos1.M, Heffernan et al.. “The Effects of Human GH and lts Lipolvtic Fraament(AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ3-AR Knock-Out Mice,"Endocrinology, vol.142,no.12,pp.5182-5189, Dec.2001.[PubMed]
2.R.Ferrer-Lorente,C.Cabot, J.-A. Fernández-López, and M.Alemany, “Combineceffects of oleoyl-estrone and a beta3-adreneraic agonist (CL316.243) on lipidstores of diet-induced overweight male Wistar rats," Life Sci., vol. 77, no. 16, pp2051-2058,Sep.2005.[PubMed]
3.F.M. Ng, J.Sun, L.Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolicstudies of a synthetic lipolvtic domain (AOD9604) of human growth hormone,Horm.Res.,vol.53,no.6,pp.274-278,2000.[PubMed]
4.M.C. Van Hout and E. Hearne, “Netnography of Female Use of the SyntheticGrowth Hormone CJC-1295: Pulses and Potions," Subst. Use Misuse, vol. 51, no.1, pp.73-84, Jan.2016.[PubMed]
5.K. Raun et al., “lpamorelin, the first selective growth hormone secretagogue,” Eur.J.Endocrinol.,vol.139,no.5,pp.552-561.NOv.1998.[PubMed]
6.E. Adeghate and A.S. Ponery, “Mechanism of ipamorelin-evoked insulin releasefrom the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no.6,pp.403-406,Dec.2004.[PubMed]
7.J.Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3.pp.569-577,Jun.2000.[PubMed]
8.M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growthhormone-releasing hormone (GHRH) analog, normalizes growth in the GHRHknockout mouse,"Am.J.Physiol.Endocrinol. Metab., vol. 291,no.6, pp.E1290-1294,Dec.2006.[PubMed]
9.M. lonescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH)persists during continuous stimulation by CJC-1295, a long-acting GH-releasinghormone analog,"J.Clin.Endocrinol. Metab., vol.91, no.12,pp.4792-4797, Dec.2006.[PubMed
10.Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille.Martin & Pellerin, lsabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan &Bridon, Dominique.(2005).hGRF1-29-Albumin Bioconjugates Activate the GRFReceptor on the Anterior Pituitary in Rats: ldentification of CJC-1295 as a LongLasting GRF Analog.[Research Gate]
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. in-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicacondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
